Renovaro to acquire predictive oncology in all-stock transaction

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data data provides a critical pathway to progress ai using the high-speed computing power provided through collaboration with nebul combines predictive oncology's ai-driven multi-omic drug discovery platform with renovaro's ai cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes los angeles, jan. 06, 2025 (globe newswire) -- renovaro inc. (nasdaq: renb), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding loi to acquire predictive oncology (nasdaq: poai) in an all-stock transaction. david weinstein, chief executive officer of renovaro, commented, “renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring.
POAI Ratings Summary
POAI Quant Ranking